In addition to the research on the use of cannabinoids in palliative treatments for.

CBD has also been shown to have neuroprotective properties in cell cultures as well as in animal models of several neurodegenerative diseases, including Alzheimer's,xii,xiii,xiv stroke,xv glutamate toxicity,xvi multiple sclerosis (MS),xvii Parkinson's disease,xviii and neurodegeneration caused by alcohol Nabiximols (trade name Sativex), which contains THC and CBD in roughly equal proportions, has been approved throughout most of Europe and in a number of other countries for the treatment of spasticity associated with MS. It has not been approved in the United States, but clinical trials are ongoing, and two recent studies reported that nabiximols reduced the severity of spasticity in MS ,xxi There have been limited clinical trials to assess the potential efficacy of CBD for the other indications highlighted; however, a recent small double-blind trial cannabidiol legal in ohio patients with Parkinson's disease found the CBD improved quality-of-life Both CBD and THC have been found to present no risk of lethal overdose However, to reduce potential side effects, medical users may be better off using cannabis with higher levels of CBD.